Navigation Links
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
Date:2/27/2009

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium -

MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral, pan-Bcl-2 inhibitor currently in double-blinded, randomized Phase II clinical trials in both prostate cancer and non-small cell lung cancer, is the lead compound in Ascenta Therapeutics' portfolio of apoptosis-triggering small molecules.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873 )

"This is the first report of several we plan to present this year from a large and growing data set demonstrating the broad therapeutic potential of AT-101," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "The evidence of resistance reversal from this refractory population supplements the earlier clinical data demonstrating robust activity with the same regimen in docetaxel-naive patients."

Initial findings from the ongoing open-label, multi-center study demonstrates that AT-101 can be administered safely with D/P in these patients. Investigators also observed clinical responses, based on both PSA and RECIST criteria, including four patients with a confirmed PR (partial response, defined as a PSA decline of 50 percent or greater).

"This first look at the data is very encouraging, particularly since all of these patients were truly refractory to docetaxel, having not simply failed to respond but actually experienced disease progression during prior therapy," said James Reeves, MD, principal investigator, Florida Cance
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
2. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... LOUIS, Aug. 30, 2011 The Board of Directors of ... its regularly scheduled board meeting that it reaffirmed the Company,s ... platform and expansion of the Odyssey ™  platform into ... Board reviewed and endorsed the commercial strategies put forth for ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, announced today that Arthur T. ... officer, will present at the Stifel Nicolaus Healthcare Conference ... p.m. Eastern Time.  Dr. Sands will provide an overview ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference 2
(Date:7/28/2014)... July 28, 2014 Mitul R. Patel, ... gathered at the MGE Management Experts Benefit Dinner May ... leaders joined the Dentists to raise funds for the ... and Girls Clubs and Youth Programs across America. The ... people with books and audio books to directly tackle ...
(Date:7/28/2014)... 2014 Dr. Alan Xenakis, MD announced today ... Funny Feelings.” The new book, DOC X MD Funny ... unique story telling style with humor and medical accuracy. The ... reader will find answers to those age-old questions that most ... people pee? Why do mosquitoes bite some and not others? ...
(Date:7/27/2014)... Zensah®, the leader in compression technology and sports medicine, has ... . The wrist support features an adjustable velcro strap and ... Epicondylitis, more commonly referred to as tennis elbow and golfers ... the tendons attached to the outside of the elbow. Although ... work the wrist and fingers turn into a tendon that ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... play a role in screening for colorectal cancer (CRC), ... rates, the American Gastroenterological Association (AGA) Institute issued minimum ... competence, a minimum of 75 endoscopically confirmed cases should ... fact that CT colonography has not yet been endorsed ...
... than other chronic conditions , , FRIDAY, Sept. 7 (HealthDay ... may well be the most disabling disease in the ... chronic physical diseases such as angina, arthritis, asthma and ... from depression, the team of international researchers found. , ...
... Home and the ... Workplace-- ... Sept. 7 Quick, convenient, quality,health care has come to the Oklahoma ... the CVS/pharmacy store in Moore at 1040,SW 19th Street. MinuteClinic ( http://www.minuteclinic.com ...
... Group, the,international generic pharmaceuticals company, today announced that ... from the U.S. Food &,Drug Administration. Distribution of ... tablets, the generic equivalent of Pfizer,s,Norvasc(R) tablets, will ... 10 mg strengths,and are indicated for the treatment ...
... BELLEVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ - Bioniche ... Canadian,biopharmaceutical company, today announced that it has ... Economic Development (RED) Program of the,Ontario Ministry ... grant,announced by the Honourable Leona Dombrowsky, Minister ...
... Medicine at The University of Nottingham, has been recognised ... of newborn babies, particularly those born prematurely, with an ... award, by the Good Clinical Practice Journal (GCPj), acknowledges ... in drug development and clinical trials. It is given ...
Cached Medicine News:Health News:Gastroenterology sets standards for CT colonography 2Health News:Gastroenterology sets standards for CT colonography 3Health News:Depression May Be World's Most Disabling Disease 2Health News:Depression May Be World's Most Disabling Disease 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Actavis Launches Amlodipine Tablets in the U.S. 2Health News:Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine 2Health News:Academic Researcher of the Year 2007 2
... Alsius heat exchange catheters connect to the ... and maintains a target temperature input by ... patient core temperature and automatically adjusts the ... catheter (0-42C), providing consistent maintenance of temperature. ...
... vascular access. Hollow stylet design ... puncture with two-part needle. Initial ... while maintaining thumb position on ... hub of the stylet. Supplied ...
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: